Harvard Heart Letter

Research we're watching: FDA approves antidote to anti-clotting drug

The FDA has approved idarucizumab (Praxbind), a drug that quickly reverses the effects of the anti-clotting medication dabigatran (Pradaxa).

To continue reading this article you must be registered.

Get Licensed Content to Harvard Health

If you are interested in licensing content from Harvard Health Publications, please contact us using our online form. Our licensing and business development professionals will help you leverage consumer health content from Harvard Medical School as a clear differentiator in helping achieve your business goals.

Contact Us

Customer Log In